Bio-Me has created a novel qPCR-based platform (in collaboration with Thermo Fisher Scientific) called Precision Microbiome Profiling (PMP™), which enables rapid (100-200 samples in 2 hours), accurate, and highly reproducible microbiome analysis down to the strain level. The output consists of ready-to-use results that can be adapted into clinical practice.
Thanks to Bio-Me’s proprietary pipeline, specific assays at the species and strain level are developed for the relevant microbial targets, resulting in customized disease, or drug-specific profiling solutions. In addition, Bio-Me offers an off-the-shelf product (PMP™ Broad Panel), which consists of approximately 100 unique assays for specific bacterial targets screening the general condition of the gut microbiome.
Bio-Me is collaborating with key opinion leaders in the microbiome space and leading academic institutions in Europe and the US. Our partners are, amongst others, pharma and biotech companies developing next-generation microbiome-modifying drugs. We support their clinical development programs with our expertise, microbiome profiling solutions, and our access to fecal samples from 13 300 individuals (including anonymized medical registries with more than 6 000 different health parameters) through our special collaboration with HUNT4.
Bio-Me collaborates on trials for several disease areas, such as cancer immuno-oncology, IBD, and colorectal cancer.
Warren Flood, PhD – Chief Executive Officer
Morten Isaksen, PhD – Founder and Chief Innovation Officer
Jean-Marc Billod, PhD – Chief Operating Officer
Runar Vige, MSc MBA – Chief Business Officer
Selected Board members
Carl Christian Gilhuus-Moe – former CEO Dynal (Dynabeads®)
Arne Materna – former VP of Product, CosmosID
Heiner Dreismann – former President and CEO of Roche Molecular Systems
Charles Stabell – former Assistant Professor Stanford University